2004
DOI: 10.1038/nrd1601
|View full text |Cite
|
Sign up to set email alerts
|

Bevacizumab

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
31
0
2

Year Published

2005
2005
2021
2021

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 53 publications
(34 citation statements)
references
References 5 publications
0
31
0
2
Order By: Relevance
“…Several studies have shown that normalization of leaky, abnormal tumor vessels is possible by applying antiangiogenic therapies such as bevacizumab (29). One study found a decrease in interstitial fluid pressure by more than 70% and augmented tumor radiation response in two different mouse models bearing human tumor xenografts after anti-vascular endothelial growth factor treatment (30).…”
Section: Discussionmentioning
confidence: 99%
“…Several studies have shown that normalization of leaky, abnormal tumor vessels is possible by applying antiangiogenic therapies such as bevacizumab (29). One study found a decrease in interstitial fluid pressure by more than 70% and augmented tumor radiation response in two different mouse models bearing human tumor xenografts after anti-vascular endothelial growth factor treatment (30).…”
Section: Discussionmentioning
confidence: 99%
“…The demonstration of a crucial role for VEGF signaling in the regulation of SEC fenestration and lipid uptake by the liver is of particular significance given the tremendous progress in the development of anti-VEGF therapies, including the recently approved cancer therapeutic drug Avastin (Genentech) (Muhsin et al, 2004). It is conceivable that continued research and drug development based on VEGF function may clarify the cellular mechanisms of plasma lipid metabolism, and provide the treatment of cardiovascular disease caused by abnormal lipoprotein metabolism and lipid uptake in the liver.…”
Section: Significancementioning
confidence: 99%
“…Molecular modeling indicates that the anilino moiety adopts a variety of low energy conformations similar to the 6-substituent. Hence, variations on the 4-anilino ring (13)(14)(15)(16)(17)(18)(19)(20) were also synthesized to probe these binding areas and to determine whether selectivity and/or potency can be influenced by substitutions on the 4-anilino moiety with the 6-phenylethyl substituent constant. Compound 8, the phenyl unsubstituted analog, was the most potent and this side chain at position-6 was maintained in compounds 13-20.…”
Section: Design Of Inhibitorsmentioning
confidence: 99%